Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Glioblastoma 1Fallopian Tube Neoplasms 1Carcinoma, Ovarian Epithelial 1

Interventions

Carboplatin 23Paclitaxel 14pembrolizumab 8liposomal doxorubicin 7Bevacizumab 5Specimen Handling 4Cyclophosphamide 4olaparib 3niraparib 3epacadostat 3Topotecan 3Taxes 3Nivolumab 3Magnetic Resonance Spectroscopy 3Gemcitabine 3Biopsy 3sarilumab 2rucaparib 2poly ICLC 2durvalumab 2cemiplimab 2STA 9090 2Injections 2Immunoglobulin G 2Drug Therapy 2Docetaxel 2Disulfides 2Cisplatin 2veliparib 1tremelimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Fallopian Tube Neoplasms × ralimetinib × Clear all
NCT01663857 2019-09-11

A Study LY2228820 for Recurrent Ovarian Cancer

Eli Lilly and Company

Phase 1/2 Completed
118 enrolled 18 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡